Intelligence
Pricing

Healthcare

Genflow Biosciences Set to Participate in BIO International Convention 2026

Author:
FAQSIR News Desk
Last Updated:
Reading Time
2 min

#Genflow Biosciences at BIO International Convention 2026

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF), a biotechnology firm focused on longevity research, has announced that Gad Berdugo, the Independent Non-Executive Chairman, will represent the company at the BIO International Convention from June 22-25, 2026. This event is recognized as one of the most significant gatherings in the biotechnology sector, attracting key players including companies, academic institutions, investors, and policymakers.

#Panel Discussion Focus

During the convention, Berdugo will join a panel discussion titled "RNA Therapeutics: Where Will We See the Greatest Technical Advances and Continued Clinical Validation in the Next 3-5 Years?" This discussion will delve into the future possibilities and innovations surrounding RNA-based therapies, underscoring the strategic focus of the company in emerging biotechnology fields.

#About Genflow's Research Initiatives

Founded in 2020, Genflow Biosciences is headquartered in the United Kingdom, with research and development facilities in Belgium. The company specializes in developing gene therapies targeting age-related diseases, seeking to enhance longevity and improve the quality of life for aging populations. Their lead compound, GF-1002, centers on a centenarian variant of the SIRT6 gene, with preclinical trials showing promising results. Additionally, a proof-of-concept clinical trial for GF-1002 in aged dogs began in March 2025, highlighting the company’s commitment to advancing its research.

#Future Prospects

Genflow is also pursuing a clinical trial to investigate the efficacy of GF-1002 in treating Metabolic Dysfunction Associated Steatohepatitis (MASH), a prevalent chronic liver condition without effective treatments currently available. The company’s initiatives align with the growing demand for innovative solutions to address the health challenges posed by an aging global population.

#Key Takeaways

  • Genflow Biosciences will participate in the BIO International Convention from June 22-25, 2026, in San Diego.
  • Chairman Gad Berdugo will take part in a significant panel discussion on RNA therapeutics.
  • The company focuses on gene therapies for age-related diseases, with its lead compound GF-1002 showing promise in preclinical trials.
  • Genflow aims to address chronic health issues like MASH, contributing to solutions for aging populations.
  • The convention serves as a platform for Genflow to engage with industry leaders and explore future collaborations.

Original source: Read original article

Frequently Asked Questions

Genflow's involvement in the BIO International Convention highlights its commitment to engaging with leading figures in the biotechnology sector. This participation can enhance visibility and may open doors for collaboration, funding, and advancements in their research efforts.
Genflow Biosciences focuses on pioneering gene therapies aimed at treating age-related diseases. Their innovative research may hold significant potential for improving health outcomes as the global population ages.
GF-1002 is currently in the proof-of-concept clinical trial phase, evaluating its effects in aged dogs. Initial preclinical results have been promising, indicating the potential for future advancements in gene therapy.
By developing therapies aimed at longevity and age-related conditions, Genflow aspires to mitigate the socio-economic burdens of a rapidly aging population, which is a pressing concern globally.
Genflow's upcoming clinical evaluations and their participation in prominent biotechnology forums mark important milestones in their efforts. Successful outcomes could enhance their credibility and catalyse further investment.
Forward-looking statements by Genflow are subject to various uncertainties and may not guarantee future performance. However, these statements reflect the company's strategic vision and could suggest growth potential if realised.
RNA therapeutics represent a cutting-edge area in biotechnology, focusing on genetic interventions. Genflow's involvement could place it at the forefront of medical innovation, particularly in addressing age-related diseases.
Investors can follow Genflow through their official website and social media channels. Regular updates and announcements provide valuable insights into their ongoing projects and strategic direction.